The Kaiser score reliably excludes malignancy in benign contrast-enhancing lesions classified as BI-RADS 4 on breast MRI high-risk screening exams

Ruxandra Iulia Milos¹ · Francesca Pipan² · Anastasia Kalovidouri³ · Paola Clauser¹ · Panagiotis Kapetas¹ · Maria Bernathova¹ · Thomas H. Helbich¹ · Pascal A. T. Baltzer¹

Received: 7 January 2020 / Revised: 8 April 2020 / Accepted: 8 May 2020 / Published online: 6 June 2020
© The Author(s) 2020

Abstract

Objectives MRI is an integral part of breast cancer screening in high-risk patients. We investigated whether the application of the Kaiser score, a clinical decision-support tool, may be used to exclude malignancy in contrast-enhancing lesions classified as BI-RADS 4 on breast MRI screening exams.

Methods This retrospective study included 183 consecutive, histologically proven, suspicious (MR BI-RADS 4) lesions detected within our local high-risk screening program. All lesions were evaluated according to the Kaiser score for breast MRI by three readers blinded to the final histopathological diagnosis. The Kaiser score ranges from 1 (lowest, cancer very unlikely) to 11 (highest, cancer very likely) and reflects increasing probabilities of malignancy, with scores greater than 4 requiring biopsy. Receiver operating characteristic (ROC) curve analysis was used to evaluate diagnostic accuracy.

Results There were 142 benign and 41 malignant lesions, diagnosed in 159 patients (mean age, 43.6 years). Median Kaiser scores ranged between 2 and 5 in benign and 7 and 8 in malignant lesions. For all lesions, the Kaiser score’s accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2. The sensitivity of the Kaiser score was high, between 95.1 and 97.6% for all lesions, and was best in mass lesions. Application of the Kaiser score threshold for malignancy (≤ 4) could have potentially avoided 64 (45.1%) to 103 (72.5%) unnecessary biopsies in 142 benign lesions previously classified as BI-RADS 4.

Conclusions The use of Kaiser score in high-risk MRI screening reliably excludes malignancy in more than 45% of contrast-enhancing lesions classified as BI-RADS 4.

Key Points
• The Kaiser score shows high diagnostic accuracy in identifying malignancy in contrast-enhancing lesions in patients undergoing high-risk screening for breast cancer.
• The application of the Kaiser score may avoid > 45% of unnecessary breast biopsies in high-risk patients.
• The Kaiser score aids decision-making in high-risk breast cancer MRI screening programs.

Keywords Breast cancer · Magnetic resonance imaging · Sensitivity and specificity · Decision support systems · Clinical · Screening

Electronic supplementary material The online version of this article (https://doi.org/10.1007/s00330-020-06945-z) contains supplementary material, which is available to authorized users.

Pascal A. T. Baltzer
pascal.baltzer@meduniwien.ac.at

¹ Department of Biomedical Imaging and Image-guided Therapy, Division of Molecular and Gender Imaging, Medical University of Vienna, Waehringer-Guertel 18-20, A-1090 Vienna, Austria
² Institute of Diagnostic Radiology, University of Udine, Udine, Italy
³ Radiology Department, Geneva University Hospital, Geneva, Switzerland

Abbreviations
AUC · Area under the curve
BI-RADS · Breast imaging reporting and data system
BRCA · Breast cancer gene
CNB · Core needle biopsy
DCIS · Ductal carcinoma in situ
DWI · Diffusion-weighted magnetic resonance imaging
MIP · Maximum intensity projections
MRI · Magnetic resonance imaging
ROC · Receiver operating characteristic
STIR · Short-T1 inversion recovery
**Introduction**

MRI provides the highest sensitivity for the detection of breast cancer [1–5] and it plays a central role in the screening of patients with a hereditary or familial high-risk for developing breast cancer [6]. To achieve a significant risk reduction, either prophylactic bilateral mastectomy or annual screening is provided in the high-risk population [7, 8]. Moreover, women at an increased risk for the development of breast cancer are usually prone to develop breast cancer at a much younger age [7] and are consequently screened from a younger age and for a longer period of time. Although these patients usually undergo multimodality screening, it has been shown that MRI is the best modality with which to detect familial breast cancer, regardless of patient age, breast density, or risk status [9, 10]. An important proportion of these lesions are MRI-only lesions [9] and it has been shown that MRI particularly detects the small (less than 10 mm in diameter) and more aggressive types of breast cancer [11]. However, it has been postulated that the imaging characteristics of cancer that develops in women at very high-risk are less specific and may resemble benign lesions (fibroadenoma-like masses and benign kinetic features) [12, 13]. Consequently, on the basis of these results, it has been recommended that, in high-risk women, small enhancing lesions should be regarded with suspicion and biopsied, or patients should be followed up at 6 months [13]. The BI-RADS lexicon can be used to describe enhancing breast lesions in a standardized and commonly understandable way.

While the BI-RADS lexicon provides a common language for lesion description in a standardized and structured approach [14, 15], it does not provide guidance on how lesions that present with certain features should be managed. The Kaiser score is able to fill this gap [16, 17]; it is a clinical decision rule that combines BI-RADS features in a simple machine-learning derived flowchart. Following the flowchart results in a diagnostic score that reflects the increasing probabilities of malignancy, ranging from 1 to 11, with scores greater than 4 requiring biopsy. As the Kaiser score combines several criteria to achieve a diagnosis, we hypothesized that the cancers detected in high-risk women could objectively be diagnosed as such using the Kaiser score, even though they might present with a circumscribed appearance that was referred to as “fibroadenoma-like” in prior works.

Consequently, we assessed the ability of the Kaiser score to diagnose malignancy in a consecutive population of histologically proven suspicious (MR BI-RADS 4), contrast-enhancing lesions diagnosed in a high-risk breast cancer patient screening program.

**Methods**

**Study population**

This study is a retrospective single-center investigation of a prospectively populated high-risk screening database. All participants in the study prospectively provided written, informed consent to the examination and use of their data and the study was approved by the local institutional review board (Medical University of Vienna). The need for additional informed consent of this retrospective analysis of the imaging data was waived by the IRB. The study included high-risk women with a proven mutation in one of the breast cancer susceptibility genes (BRCA-1 or BRCA2) or those who fulfilled the criteria of increased familial risk as described previously [9, 14, 18, 19]. The family history inclusion criteria for high-risk screening in Austria are the following: (a) three breast cancers at age ≤ 60 years; (b) two breast cancers at age ≤ 50 years; (c) one breast cancer at age ≤ 35 years; (d) one breast cancer at age ≤ 50 years and one ovarian cancer at any age; (e) two ovarian cancers at any age; and (f) one male and one female cancer at any age. All the affected first-degree relatives must be on the same side of the family. A woman’s personal cancer history can contribute to the criteria. Women who fulfilled these family history criteria were advised to undergo genetic testing at our institution, but remained within the study even if they decided not to be tested or if the tests were negative for a breast cancer susceptibility gene.

All study patients underwent annual screening, consisting of two-view mammography, ultrasound, and MR imaging of the breast every 12 months, with a maximum interval of 1 month between the individual modalities [9, 19].

From our prospectively populated, high-risk screening database, we selected all 197 consecutive patients from February 2003 to August 2015 (mean age, 43.6 ± 11.2 years; age range, 23–80) who underwent 257 image-guided biopsies (either ultrasound-, stereotactic-, or MRI), both core needle biopsy (CNB) and vacuum-assisted breast biopsy (VABB), at our institution, a tertiary care university hospital. Excluded were all cases that underwent biopsy due to findings not visible on MRI (e.g., mammographic or sonographic abnormalities that did not present as enhancing lesions on MRI), all patients with lesions in which localization was not clear upon retrospective review (e.g., patients who underwent ultrasound-guided biopsy of subtle anomalies which could not be connected to a localized enhancing lesion on MRI), and patients whose diagnostic MR images could not be retrieved electronically, as they were either corrupted or stored on non-compatible DICOM storage. Details are given in the patient and lesion selection flowchart (see supplementary Figure 1). The final study database consisted of 183 breast MRI-visible lesions classified as BI-RADS 4 in 159 patients (mean age, 43.6 ± 11.6 years; age range, 24–80). Parts of our institutional high-

VABB: Vacuum-assisted breast biopsy
VIBE: Volumetric interpolated breath-hold examination
risk screening database were used in prior publications [9, 14], with substantially different rationales and results.

**Imaging and image-guided biopsies**

Until September 2008, MRI of the breast was performed on a 1.0-T scanner with a dedicated double breast coil (Gyrosan T10-NT; Philips). The MRI sequence protocol consisted of a sagittal T2-weighted STIR sequence and axial, T1-weighted, three-dimensional, gradient-echo dynamic sequences. Images were obtained once before intravenous contrast agent administration and six times at intervals of 70 s thereafter. After September 2008, a 1.5-T MRI scanner MAGNETOM Avanto (Siemens) was used. After a sagittal T2-weighted sequence with fat suppression (turbo inversion recovery magnitude), axial T1-weighted dynamic sequences were measured once before and four times after contrast agent injection at intervals of 90 s. In 2013, the protocol was modernized, changing the axial dynamics to a high-spatial-resolution, Dixon fat-suppressed VIBE sequence while maintaining the temporal resolution of 90 s. In addition, precontrast axial T2w-TSE, STIR, and DWI sequences were introduced as recommended in [16].

To minimize hormone-related background breast tissue enhancement, premenopausal women were scheduled on the seventh to the fourteenth day of their menstrual cycle [8].

All lesions classified as BI-RADS 4 (suspicious) were biopsied using image guidance (either CNB or VABB was performed according to already established guidelines [20–23]) or surgically biopsied [24]. All biopsy specimens underwent histopathological analysis, the gold standard of our study. Histopathological tissue analysis was performed by an experienced, board-certified breast pathologist (M.R.). The B classification for diagnosis was applied [25]. In all patients with malignant lesions, i.e., invasive carcinoma and/or ductal carcinoma in situ (DCIS), and in lesions with uncertain malignant potential (histopathological B3), surgical biopsy was performed, after wire localization. In case of a benign finding at histopathology, the patients underwent follow-up with breast MRI at 12 months (according to the annual high-risk screening).

**Data analysis**

All 183 included cases were independently analyzed by three breast imaging radiologists, who were blinded to the final histopathological diagnosis. The readers were breast fellowship-trained radiologists trained at three different institutions. All had similar prior experience between 3 and 5 years.

Masses were classified according to their BI-RADS lexicon appearance into mass, non-mass, and foci. The readers were asked to classify all biopsied lesions using the Kaiser score as described in the literature [16] and did not undergo formal training before reading the study cases. This score combines five independent morphological and kinetic BI-RADS lexicon-derived descriptors (internal enhancement, lesion margins, presence of spiculations (formerly referred to as “root sign” [14]), SI-time-curve type, and presence of edema) in a flowchart-like algorithm. The resulting score reflects the increasing probabilities of malignancy (1 = lowest, cancer very unlikely to 11 = highest, cancer very likely) [16]. Scores greater than 4 require biopsy. A diagnostic category was assigned for each biopsied lesion.

**Statistical analysis**

Statistical analysis was performed by P.B. using SPSS 23.0 (SPSS, IBM) and MedCalc 18 (MedCalc software bvba). A receiver operating characteristic (ROC) analysis was performed and the area under the ROC curve was measured to determine overall diagnostic performance. Sensitivity and specificity were calculated at a cutoff value of > 4, which indicated malignancy. Inter-reader agreement of the dichotomized (Kaiser scores 1–4 were considered benign, 5–11 malignant) Kaiser score readings was assessed using kappa statistics. Cross-tabulated data were compared by the chi-squared test. p values ≤ 0.05 were considered statistically significant.

**Results**

**Lesion characteristics**

The study cohort included 159 patients with 183 histologically verified lesions (see supplementary Figure 1). In total, 121 of these lesions were examined and biopsied before 2009, 62 afterwards. The mean size of the 41 malignant lesions (17.5 \pm 13.8 mm) was significantly higher than that of the 142 benign lesions (11–6 \pm 7.5 mm, p = 0.010, Mann-Whitney U test). There were 88 mass lesions, 48 non-mass lesions, and 47 foci. Of all 88 mass lesions, 24 (27.3%) were malignant and 64 benign. Of the 48 non-mass lesions, 10 (20.8%) were malignant and 38 benign. Seven (14.9%) of the 47 foci were malignant and 40 benign. Detailed histopathological diagnoses and subtypes are given in Table 1.

**Inter-reader agreement**

The kappa agreement among the three readers for the characterization of breast lesions according to the Kaiser score was fair to moderate (R1 vs R2, 0.393; R1 vs R2, 0.362; R2 vs R3, 0.560). The median Kaiser scores in benign lesions were 5, interquartile range (IQR) 2–6 (R1); 2, IQR 2–5 (R2); and 3, IQR 1–5 (R3). In malignant lesions, median Kaiser scores...
were 8, IQR 7–10 (R1); 7, IQR 5–9 (R2); and 8, IQR 5–9 (R3) (see Fig. 1).

**ROC curve analyses**

Detailed results about the diagnostic performance of the Kaiser score in all lesions, masses, non-mass lesions, and foci are shown in Tables 2 and 3 and Fig. 2.

**Table 1** Final histological characteristics of the biopsied lesions

| Subtype                                                                 | n (%)         |
|------------------------------------------------------------------------|---------------|
| **Benign**                                                             |               |
| Adenosis, sclerosing adenosis                                          | 41/142 (28.9%)|
| Fibroadenoma, fibroadenomatoid hyperplasia                             | 23/142 (16.2%)|
| Benign epithelial proliferations                                       | 41/142 (28.9%)|
| Benign breast tissue, pseudoangiomatous stromal hyperplasia           | 25/142 (17.6%)|
| Inflammation                                                           | 1/142 (0.7%)  |
| B3 lesion                                                              | 11/142 (7.7%) |
| **Malignant**                                                          |               |
| **DCIS**                                                               |               |
| Luminal A type                                                         | 7/12 (58.3%)  |
| Luminal B type                                                         | 0/12 (0%)     |
| Her2 type                                                              | 5/12 (41.7%)  |
| Triple negative                                                        | 0/12 (0%)     |
| **Invasive cancer**                                                   |               |
| Luminal A type                                                         | 11/29 (38.0%) |
| Luminal B type                                                         | 6/29 (20.7%)  |
| Her2 type                                                              | 3/29 (10.3%)  |
| Triple negative                                                        | 9/29 (31.0%)  |

**Table 2** Diagnostic performance indices for all three readers including subgroups of mass, non-mass lesions, and foci

|                       | AUC  | 95% CI         |
|-----------------------|------|----------------|
| **All lesions (183)** |      |                |
| Reader 1              | 90.2 | 85.0–94.1      |
| Reader 2              | 86.5 | 80.7–91.1      |
| Reader 3              | 87.5 | 81.8–91.9      |
| **Mass (88)**         |      |                |
| Reader 1              | 89.5 | 81.1–95.0      |
| Reader 2              | 89.3 | 80.8–94.9      |
| Reader 3              | 85.4 | 76.2–92.0      |
| **Non-mass (48)**     |      |                |
| Reader 1              | 89.0 | 76.5–96.2      |
| Reader 2              | 76.3 | 61.8–87.4      |
| Reader 3              | 93.6 | 82.5–98.6      |
| **Foci (47)**         |      |                |
| Reader 1              | 92.3 | 80.7–98.1      |
| Reader 2              | 87.7 | 74.8–95.4      |
| Reader 3              | 79.8 | 65.6–90.1      |

Values are given as percentages, absolute numbers in brackets; AUC, area under the receiver operating characteristics curve; CI, confidence interval.

**Area under the ROC-curve**

Using the Kaiser score for all lesions, the overall accuracy, represented by the area under the curve (AUC), ranged between 86.5 and 90.2 (Table 2). Taken separately, for mass
Table 3  Sensitivity and specificity for all three readers including subgroups of mass, non-mass lesions, and foci

|                  | Sensitivity (TP/TP + FN) | 95% CI       | Specificity (TN/TN + FP) | 95% CI       |
|------------------|--------------------------|--------------|--------------------------|--------------|
| All lesions (183) |                          |              |                          |              |
| Reader 1         | 97.6 (40/41)             | 87.1–99.9    | 45.1 (64/142)            | 37.4–54.3    |
| Reader 2         | 92.7 (38/41)             | 83.5–99.4    | 67.6 (96/142)            | 59.2–75.2    |
| Reader 3         | 95.1 (39/41)             | 80.1–98.5    | 72.5 (103/142)           | 64.4–79.7    |
| Mass (88)        |                          |              |                          |              |
| Reader 1         | 100 (24/24)              | 85.8–100     | 39.1 (25/64)             | 27.1–52.1    |
| Reader 2         | 100 (24/24)              | 85.8–100     | 64.1 (41/64)             | 51.1–75.7    |
| Reader 3         | 100 (24/24)              | 85.8–100     | 60.9 (39/64)             | 47.9–72.9    |
| Non-mass (48)    |                          |              |                          |              |
| Reader 1         | 100 (10/10)              | 69.2–100     | 36.8 (14/38)             | 21.8–54      |
| Reader 2         | 80 (8/10)                | 44.4–97.5    | 52.6 (20/38)             | 35.8–69.0    |
| Reader 3         | 100 (10/10)              | 69.2–100     | 79.0 (30/38)             | 62.7–90.4    |
| Foci (47)        |                          |              |                          |              |
| Reader 1         | 85.7 (6/7)               | 42.1–99.6    | 62.5 (25/40)             | 45.8–77.3    |
| Reader 2         | 85.7 (6/7)               | 42.1–99.6    | 87.5 (35/40)             | 73.2–95.8    |
| Reader 3         | 71.4 (5/7)               | 29.0–96.3    | 85.0 (34/40)             | 50.9–81.4    |

Values are given as percentages, absolute numbers in brackets; TP, true positives; TN, true negatives; FP, false positives; FN, false negatives; CI, confidence interval

Fig. 2  Receiver operating characteristic (ROC) curves for all three readers. All lesions are given in the upper left, non-mass lesions in the upper right, foci in the lower left, and mass lesions in the lower right. Diagnostic performance estimates are summarized in Table 2.
lesions, the AUC for lesion diagnosis ranged between 85.4 and 89.5, whereas in non-mass lesions, the AUC varied between 76.3 and 93.6. For foci, the AUC ranged between 79.8 and 92.3 (Table 2).

**Sensitivity and false-negative findings**

The sensitivity of the Kaiser score was high, between 92.7 and 97.6% for all lesions, 100% for mass lesions, and 80 to 100% for non-mass lesions, while for foci, it was lower, with 71.4 to 85.7% (Table 3). Four (two foci and two non-mass lesions) of the 41 malignant lesions were missed. One of the seven malignant foci (luminal A type invasive cancer) was missed by all three readers (Kaiser scores 3, 4, and 4, respectively). Reader 2 reported two additional false-negative non-mass lesions (one luminal A type invasive cancer, and one HER 2 type DCIS, Kaiser scores 3 and 4, respectively), while reader 3 failed to identify one additional focus as malignant (luminal A type invasive cancer, Kaiser score 1). All false-negative readings were diagnosed before 2009, when the scanner was changed from 1.0 to 1.5 T. Of the 41 cancers, 22 were diagnosed prior to 2009 and 19 afterward. The difference between false-negative findings before and after this date was not statistically significant ($p > 0.05$, respectively).

**Specificity and the potential to avoid unnecessary biopsies**

The specificity for all lesions ranged between 45.1 and 72.5% (Table 3). The application of the Kaiser score improved diagnosis by correctly identifying between 64 (45.1%) and 103 (72.5%) of 142 benign lesions previously classified as BI-RADS 4. Accordingly, 25 to 41 mass lesions (28.4 to 46.6%), 14 to 30 non-mass lesions (29.2 to 62.5%), and 25 to 34 foci (53.2 to 72.3%) could have been predicted using the Kaiser score with a cutoff value of 4. Thus, biopsies could have been avoided in a large percentage of cases. Examples are given in Figs. 3, 4, 5, and 6.

**Discussion**

This study investigated the benefit of implementing the Kaiser score as a decision tool in MRI suspicious (BI-RADS 4) contrast-enhancing lesions diagnosed in patients at high-risk for developing breast cancer. This is clinically highly relevant as it refutes the notion of benign-appearing cancers in the investigated setting. Furthermore, we could show that the Kaiser score is applicable in high-risk patients independent of lesion appearance as mass, non-mass, or foci. The diagnostic performance equaled that of the Kaiser score applied in other scenarios [26–28]. The thresholds established in other indications could be reproduced, allowing exclusion of cancer with high certainty. Potentially, 45 to 72% of all unnecessary biopsies could have been avoided by applying the Kaiser score prior to biopsy.

The Kaiser score uses a small set of morphological and dynamically relevant features that were chosen by machine-learning methodology (presence of spiculations/root sign, enhancement kinetics, lesion margin, internal enhancement pattern, and ipsilateral edema). The result is a three-step flowchart with the score providing the probabilities of malignancy, ranging from 1 to 11. Thus, enhancing lesion assessment can be simplified and structured and the results can be used for evidence-based decision-making. Scores below 5 should be considered benign, while histological workup is mandatory for higher scores [16]. This was initially tested in an exploratory study on biopsy-proven lesions in a mixed study population [17] and thereafter validated in consecutive problem-solving cases [26], suspicious MRI-only lesions [27], and in lesions that presented as suspicious mammographic microcalcifications [28]. The application of the Kaiser score relies on generally recommended standard breast MRI protocols (T2-weighted sequences and dynamic, contrast-enhanced, T1-weighted sequences), and it was shown to be independent of the type of scanners/vendors used [27] and helpful for less experienced radiologists [26]. It does not require any additional functional imaging, such as DWI or MR spectroscopy, or postprocessing software [17]. Yet, it allows the...
integration of further diagnostic data, either clinical (such as bloody discharge), conventional findings (e.g., suspicious mammographic calcifications), or quantitative information (e.g., DWI), as discussed in [16].

We found that the Kaiser score is highly accurate in the setting of high-risk patients. All readers achieved a high sensitivity, with the only false-negative results in non-mass lesions and foci. This could be explained by the difficulty of determining the margin type or discerning the enhancement pattern in lesions smaller than 5 mm, especially on old examinations of a lower quality. Notably, although statistically not significant due to a low sample size, all false-negative ratings were obtained in examinations older than 10 years, stressing the importance of high image quality for interpretation of these lesions. The already established cutoff value for a biopsy recommendation in Kaiser scores exceeding 4 [16, 26, 27] was applicable in our study cohort. Thus, even if initially categorized as BI-RADS 4 lesions, scores of 4 or lower were robustly indicative of a benign outcome. Diagnostic tests are not perfect. If low Kaiser scores are applied to avoid unnecessary biopsies, this comes at the cost of false-negative findings: missed cancers. In healthcare, the application of a decision-making tool such as the Kaiser score is always an ethical issue: how many avoided unnecessary biopsies are worth one missed cancer? None of the false-negative lesions presented as masses on MRI. We think it is safe to conclude that the Kaiser score can without a doubt be safely applied to downstage mass lesions but caution should be used when interpreting non-mass lesions and foci. The number of false-negative findings in this study was low: lesions were either luminal A type invasive cancer or DCIS. It can therefore be safely assumed that downgrading a lesion would not have changed the patients’ prognosis but rather led to a delayed diagnosis in a biologically less significant malignancy. Patients in this setting undergo annual screening, equaling the maximum diagnostic delay. Whether such downgraded lesions should be primarily assigned BI-RADS 3 and undergo an additional follow-up at 6 months is discussed elsewhere [29].

The results once more corroborate the usefulness of a structured and evidence-based diagnostic approach. In high-risk MRI screening, the low prevalence of malignancy is connected to an inherent risk of false-negative findings [30]. Radiologists seemingly compensate for this by using a rather low biopsy threshold. Although the 5th BI-RADS lexicon edition [15] can be used for standardized lesion description [14], the results of our paper point out the limitations of empirical BI-RADS 4 category assignments that do not follow objective rules in high-risk patients.

Previous studies have shown that the imaging phenotypes of malignancy differed in women at high risk, with a high percentage of invasive cancers appearing as fibroadenoma-like masses, but without fibroadenoma-like internal enhancement or enhancement kinetics [12, 31]. However, our results demonstrate

![Fig. 4](image-url) A 35-year-old high-risk patient: MRI (a T2w; b, c subtracted early and late contrast-enhanced, T1-weighted images) shows a circumscribed mass lesion with heterogeneous internal enhancement and wash-out, corresponding to a Kaiser score of 8. Note the hyperintense, fibroadenoma-like T2w-correlate (a). Histology revealed a triple-negative invasive ductal cancer, B5b

![Fig. 5](image-url) A 39-year-old high-risk patient: MRI (a T2w; b, c subtracted early and late contrast-enhanced, T1-weighted images) shows a circumscribed mass lesion with heterogeneous internal enhancement and persistent signal increase, corresponding to a Kaiser score of 1. Note the fibroadenoma-like T2w-correlate (a). Histopathology revealed a fibroadenoma, B2
that there are no cancers with exclusively benign criteria. The structured combination of morphological and functional criteria provided by the Kaiser score avoids misinterpretations of a single diagnostic criterion such as circumscribed margins.

The combination of diagnostic criteria is available due to the multiparametric character of breast MRI. Recently, alternative, abbreviated protocols have been proposed for screening women with dense breast tissue [6, 32]. The aim is to reduce the scan time by acquiring only one pre-contrast and one early post-contrast T1-weighted image set. Consequently, the reader can obtain a quick overview of presence or absence of enhancement on a single, high-contrast, maximum intensity projection (MIP) image, followed by subsequent characterization of enhancement with respect to configuration, morphology, margins, and internal architecture based on an analysis of the individual subtracted images [32]. Nonetheless, the shape of the enhancement curve was shown to be relevant for estimating the probability of malignancy, increasing from a type I (persistent) to a type III (wash-out) curve. In the framework of the machine learning–derived Kaiser score, the enhancement curve type is the second most important diagnostic criterion. Thus, in the setting of a high-risk patient, with no information about the enhancement kinetics, a circumscribed lesion with enhancement must always be considered suspicious. Our study, therefore, provides indirect evidence against abbreviated, non-dynamic protocols for high-risk screening: due to the lack of diagnostic information provided by the enhancement kinetics, unnecessary biopsies will be performed. While the alternative approach of ultrafast early perfusion imaging may potentially compensate for that, its applicability for avoiding unnecessary biopsies in a combined diagnostic model has not yet been proven.

The main limitation of this study was that the MRI scans analyzed were acquired with old protocols and on different MRI equipment, with different field strengths and sequence parameters. This was not unavoidable, as patients were recruited consecutively from a longitudinal, prospective, high-risk screening study. On the other hand, this limitation can also be seen as a strength, as it corroborates the general applicability of the Kaiser score, which is based on regular BI-RADS features intended to be used independent from MRI protocols and scanning equipment. Nevertheless, the heterogeneous image quality may be the reason only a fair-to-moderate inter-reader agreement could be achieved, in contradiction to previously reported data [26, 27]. Another reason for this might be the fact that readers were not trained before the study as it was done in a previous study, further contributing to inter-reader variation [14].

In conclusion, this study provides evidence that the Kaiser score may be used in high-risk patients recalled from screening due to the detection of BI-RADS 4 lesions to avoid unnecessary biopsies, in particular those lesions presenting as masses. This has a positive potential to impact healthcare costs, as well as patient concern.

**Funding information** Open access funding provided by Medical University of Vienna. This study has received no dedicated funding.

**Compliance with ethical standards**

**Guarantor** The scientific guarantor of this publication is Pascal A.T. Baltzer.

**Conflict of interest** The authors of this manuscript declare no relationships with any companies, whose products or services may be related to the subject matter of the article.

**Statistics and biometry** One of the authors has significant statistical expertise.

**Informed consent** Written informed consent was obtained from all subjects (patients) in this study.

**Ethical approval** Institutional Review Board approval was obtained.

**Study subjects or cohorts overlap** The investigated patients are part of the national high-risk breast cancer screening program conducted at our institution. Several reports in other contexts (no overlap of rationale or results) have been published, the patient overlap of the more recent reports 1 and 2 is > 80%:

- Marino MA, Riedl CC, Bernathova M, et al (2018) Imaging phenotypes in women at high risk for breast cancer on mammography, ultrasound, and magnetic resonance imaging using the fifth edition of the...
breast imaging reporting and data system. Eur J Radiol 106:150–159. https://doi.org/10.1016/j.ejrad.2018.07.026

Riedl CC, Luft N, Bernhart C, et al (2015) Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33:1128–1135. https://doi.org/10.1200/JCO.2014.56.8626

Riedl CC, Ponhold L, Flöry D, et al (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 13:6144–6152. https://doi.org/10.1158/1078-0432.CCR-07-1270

Methodology
- retrospective
- cross-sectional observational study
- performed at one institution

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Houssami N, Ciatto S, Macaskill P, et al (2008) Accuracy and surgical impact of magnetic resonance imaging in breast cancer staging: systematic review and meta-analysis in detection of multifocal and multicentric cancer. J Clin Oncol 26:3248–3258

2. Pinker K, Helbich TH, Morris EA (2017) The potential of multiparametric MRI of the breast. Br J Radiol 90:20160715

3. Warner E, Messersmith H, Eisen A, Shumak R, Plewes D (2008) Systematic review: using magnetic resonance imaging to screen women at high risk for breast cancer. Ann Intern Med 148:671–679

4. Bennani-Baiti B, Baltzer PA (2017) MR imaging for diagnosis of malignancy in mammographic microcalcifications: a systematic review and meta-analysis. Radiology 283:692–701

5. Bennani-Baiti B, Bennani-Baiti N, Baltzer PA (2016) Diagnostic performance of breast magnetic resonance imaging in non-calcified equivocal breast findings: results from a systematic review and meta-analysis. PLoS One 11:e0160346

6. Mann RM, Kuhl CK, Moyer L (2019) Contrast-enhanced MRI for breast cancer screening. J Magn Reson Imaging 50(2):377–390. https://doi.org/10.1002/jmri.26654

7. (2013) Familial breast cancer: classification and care of people at risk of familial breast cancer and management of breast cancer and related risks in people with a family history of breast cancer. National Collaborating Centre for Cancer (UK), Cardiff (UK). https://www.ncbi.nlm.nih.gov/books/NBK247567/

8. Mann RM, Balleyguier C, Baltzer PA et al (2015) Breast MRI: EUSOBI recommendations for women’s information. Eur Radiol 25:3669–3678

9. Riedl CC, Luft N, Bernhart C, et al (2015) Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. J Clin Oncol 33:1128–1135

10. Warner E, Plewes DB, Hill KA et al (2004) Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA 292:1317–1325

11. Sardenelli F, Podo F (2007) Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol 17:873–887

12. Schrading S, Kuhl CK (2008) Mammographic, US, and MR imaging phenotypes of familial breast cancer. Radiology 246:58–70

13. Gilbert FJ, Warren RM, Kwan-Lim G, et al (2009) Cancers in BRCA1 and BRCA2 carriers and in women at high risk for breast cancer: MR imaging and mammographic features. Radiology 252:358–368

14. Marino MA, Riedl CC, Bernathova M, et al (2018) Imaging phenotypes in women at high risk for breast cancer on mammography, ultrasound, and magnetic resonance imaging using the fifth edition of the breast imaging reporting and data system. Eur J Radiol 106:150–159

15. D’Orsi CJ, Sickles EA, Mendelson EB, Morris EA et al (2013) ACR BI-RADS® atlas, breast imaging reporting and data system. Reston, American College of Radiology

16. Dietzel M, Baltzer PAT (2018) How to use the Kaiser score as a clinical decision rule for diagnosis in multiparametric breast MRI: a pictorial essay. Insights Imaging 9:325–335

17. Baltzer PA, Dietzel M, Kaiser WA (2013) A simple and robust classification tree for differentiation between benign and malignant lesions in MR-mammography. Eur Radiol 23:2051–2060

18. Singer CF, Tea MK, Pristaz G, et al (2015) Clinical practice guideline for the prevention and early detection of breast and ovarian cancer in women from HBOC (hereditary breast and ovarian cancer) families. Wien Klin Wochenschr 127:981–986

19. Riedl CC, Ponhold L, Flöry D, et al (2007) Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res 13:6144–6152

20. Hahn M, Krainick-Strobel U, Toellner T, et al (2012) Interdisciplinary consensus recommendations for the use of vacuum-assisted breast biopsy under sonographic guidance: first update 2012. Ultraschall Med 33:366–371

21. Heywang-Kobrunner SH, Lebeau A, et al (2009) Interdisciplinary consensus on the uses and technique of MR-guided vacuum-assisted breast biopsy (VAB): results of a European consensus meeting. Eur J Radiol 72:289–294

22. Heywang-Kobrunner SH, Schreer I, Decker T, Bocker W (2003) Interdisciplinary consensus on the use and technique of vacuum-assisted stereotactic breast biopsy. Eur J Radiol 47:232–236

23. Zhang C, Lewis DR, Nasute P, Hayes M, Warren LJ, Gordon PB (2012) The negative predictive value of ultrasound-guided 14-gauge core needle biopsy of breast masses: a validation study of 339 cases. Cancer Imaging 12:488–496

24. Perry NBM, de Wolf C, Törnberg S, Holland R, von Karsa L, Puthaar E (eds) (2006) European guidelines for quality assurance in breast cancer screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg, pp 219–255

25. Perry NBM, de Wolf C, Törnberg S, Holland R, von Karsa L, Puthaar E (eds) (2006) Quality assurance guidelines for pathology in European guidelines for quality assurance in breast cancers screening and diagnosis, 4th edn. Office for Official Publications of the European Communities, Luxembourg, pp 219–255
26. Marino MA, Clauser P, Woitek R et al (2016) A simple scoring system for breast MRI interpretation: does it compensate for reader experience? Eur Radiol 26:2529–2537
27. Woitek R, Spick C, Schernthaner M et al (2017) A simple classification system (the Tree flowchart) for breast MRI can reduce the number of unnecessary biopsies in MRI-only lesions. Eur Radiol 27:3799–3809
28. Wengert GJ, Pipan F, Almohanna J et al (2020) Impact of the Kaiser score on clinical decision-making in BI-RADS 4 mammographic calcifications examined with breast MRI. Eur Radiol 30:1451–1459
29. Spick C, Bickel H, Polanec SH, Baltzer PA (2018) Breast lesions classified as probably benign (BI-RADS 3) on magnetic resonance imaging: a systematic review and meta-analysis. Eur Radiol 28:1919–1928
30. Kriege M, Brekelmans CT, Boetes C et al (2004) Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 351:427–437
31. Veltman J, Mann R, Kok T et al (2008) Breast tumor characteristics of BRCA1 and BRCA2 gene mutation carriers on MRI. Eur Radiol 18:931–938
32. Kuhl CK (2018) Abbreviated breast MRI for screening women with dense breast: the EA1141 trial. Br J Radiol 91:20170441

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.